Truro café serving healthy coffees and smoothies opens
A new café serving healthy coffees and smoothies has opened in Truro.
Luxe, run by Leeann Griffith, specialises in natural skin and body treatments and has now expanded with a ground-floor bar.
The café puts an "adaptogenic and nootropic twist" on hot and cold drinks.
Adaptogens, found in plants and fungi, are said to help the body manage stress, anxiety, and fatigue.
Common examples include ginseng, turmeric, and ashwagandha.
Nootropics such as ginkgo biloba and fish oils, often referred to as cognitive enhancers, are believed to improve thinking, learning, and memory.
Leeann has been working from the first floor of the building in New Bridge Street since March last year, offering natural and medical-grade skin treatments, as well as food intolerance and hormone testing, especially for fertility and menopause.
Her interest in natural skincare began while working as a dental nurse.
She said: "My boss sent me for training in Botox and fillers, but by the time I'd qualified, he'd changed his mind about offering them.
"I didn't particularly like Botox, but had started to research natural treatments, did more courses and found a new job with a surgery that wanted to offer aesthetics."
Having decided to go solo after the pandemic, Ms Griffith settled into her new premises and created a menu of hot and cold drinks aimed at boosting physical and mental wellbeing.
These are available to all customers, not just those receiving treatments.
Shakes include the high-protein Choc-o-Luxe, containing banana, avocado, nut butter, collagen, and raw cacao nibs.
There is also the Matcha Power with blueberries and Clean Green with kale and mango.
A range of adaptogenic black coffees and superfood lattes contains ingredients such as collagen, lion's mane fungi, beetroot, and peppermint.
Leeann borrowed £4,000 through a Start-Up Loan for cashflow and to cover the cost of an employee to staff the bar.
She said: "I'm a single mum-of-two, so I needed a bit of extra help.
"Bank interest rates were really high.
"SWIG was a good experience.
"Jo was lovely and it was nice to have a more personal approach, rather than an algorithm."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
The most depressing jobs in the country revealed in new study
Job seekers may want to consider the toll that specific careers can have on their mental health. A huge new study published on Friday examined the relationship between careers and depression rates. The study analyzed survey data from 536,279 workers across 37 states from 2015 to 2019. Out of half a million U.S. workers, 80,319 of them admitted to being diagnosed with depression at some point during their lives, with women being diagnosed twice as often as men. Separating the results by industry, the study saw that people who worked in community and social services had the highest rate of lifelong diagnosed depression at 20.5 percent. The second highest on the list was food prep and serving jobs at 20.1 percent. Other industries with high lifetime diagnosed depression rates are: arts, entertainment, sports, and media at 18.6 percent; accommodation and food services at 18.4 percent; health and social assistance at 18.2 percent; retail trade at 17.7 percent; and legal, education, and library jobs tied at 16.1 percent. Industries with lower lifetime diagnosed depression rates included mining jobs at 6.7 percent, construction at 8.9 percent, and agriculture and engineering jobs at nine percent. Although mining and construction may have lower depression rates, those industries also have the highest suicide rates among U.S. workers. The researchers suggest that the gap may be explained because blue-collar men are less likely to seek mental services due to a preexisting stigma or limited access in rural areas. Despite the results of the study, there are some jobs out there that are almost stress-free and also come with a large paycheck. Back in December 2024, Resume Genius released its list of the highest-paying jobs that also reported low levels of stress. Their study described 'low-stress jobs' as ones that typically require fewer demands, more predictable work hours, supportive environments, and manageable workloads. All of the jobs on the list required the person to have at least a Bachelor's degree. The list was compiled using data from the U.S. Bureau of Labor Statistics (BLS) and the career site O*NET Online. The high-stress jobs were filtered out using O*NET and then cross-referenced against the BLS's Occupational Outlook Handbook, with the national median salary set at $48,060 and viewing jobs that showed 'faster-than-average growth.' The best jobs included: water source specialist, astronomer, actuary, environmental economist, mathematician, and geographer.
Yahoo
2 days ago
- Yahoo
KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO")
Recent clinical and pre-clinical studies and analysis indicates the potential to increase lifespan and reduce age-associated degeneration in multiple organ systems has be realized with a focus on the human gene called Klotho. NEW YORK, June 9, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company announced the findings of pre-clinical studies indicating the potential of elevating Klotho gene expression to simultaneously reduce the age-associated degeneration in multiple organs, increasing both life and health span. Pioneering discoveries by Professor Makoto Kuro-O in 1997 showed that Klotho concentrations in the blood were directly associated with lifespan of mammals – the lower the Klotho blood levels the shorter the lifespan. Kuro-O's laboratory then published the first evidence that genetic over expression of the full-length form of Klotho in mice, increased in lifespan of mice of up to 30%-40% longer compared to the normal mouse lifespan. Since then, the Klotho protein has gained much attention because of its ability to influence key biological pathways involved in metabolism, inflammation and tissue repair, which are closely linked to the aging process. A series of experiments led by Joan Roig-Soriano and colleagues, published in the February 2025 edition of Molecular Therapy, highlights the promising role of the naturally occurring secreted form of the Klotho protein ("s-KL") and its effects on healthy aging mice and mice with a rapidly aging phenotype. Key observations were that, while aging is a major risk factor for many pathologies, including cognitive decline, neuroinflammation, sarcopenia, and osteoporosis, the secreted protein s-KL has emerged as a potentially promising therapeutic anti-aging molecule due to its many biological effects involving multiple pathways related to cell injury, stress, and inflammation. The s-KL was administered using an adeno-associated virus serotype 9 delivery vector (AAV9) that expressed the secreted KL protein isoform and efficiently increased the concentration of s-KL in serum, resulting in a 20% increase in lifespan. Dr. Joseph Sinkule, the CEO of Klotho Neurosciences (KLTO) commented that "KLTO has secured an exclusive worldwide license for s-Kl from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Spain. As a result, we have the exclusive use of patents issued in the USA, Europe, and China covering a secreted splice variant of mammalian Klotho referred to as s-KL, as a treatment for neurodegenerative and age -related disorders. Professor Makoto Kuro-O is also a scientific advisor to KLTO. This recently published paper provides further credence to our development of s-KL as a treatment to reduce age-associated degeneration where, as a company, KLTO has a particular focus on neurodegenerative diseases such as ALS, Alzheimer's and Parkinson's disease. The results disclosed in the paper show the potential of elevating s-KL protein expression, resulting in the reduction of age-associated degeneration in multiple organs, increasing both life and health span". About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and it's novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. For more information, contact:Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFOjeff@ Website: Forward-Looking Statements: This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC's website, All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. View original content to download multimedia: SOURCE Klotho Neurosciences, Inc.
Business of Fashion
3 days ago
- Business of Fashion
L'Oréal to Acquire British Skincare Brand Medik8
L'Oréal has acquired a majority stake in British skincare brand Medik8, the companies announced Monday. The brand will be managed under the beauty giant's Luxe division, sitting alongside premium lines like Aesop and Kiehl's. The terms of the transaction were not disclosed, though a recent report in the Financial Times said the brand was valued at roughly $1 billion. Medik8, which was founded in 2009 by Elliot Isaacs, sells science-backed serums that are designed to preserve and restore skin, including its popular Liquid Peptides ($66) and Crystal Retinal ($85) ranges. It has a production and research facility in Buckinghamshire, England, where it manufactures its products. In 2021, Medik8 was acquired by private equity firm Inflexion. Sales reached $70 million to $80 million in 2024, following a push into the US market. Science-backed skincare has been a boon for L'Oréal, which also owns other 'dermocosmetics' brands like the mass lines Cerave and La Roche Posay, as well prestige names like Skinceuticals and Skinbetter Science. 'We share a strong belief in Medik8's global potential,' said Cyril Chapuy, president of L'Oréal Luxe, in a statement. Sign up to The Business of Beauty newsletter, your complimentary, must-read source for the day's most important beauty and wellness news and analysis. Beauty's Top M&A Targets for 2025 After a slow year for acquisitions, brands and investors alike are hoping that 2025 will yield bigger exits. But with most strategic buyers like L'Oréal operating with an even narrower lens, only a select few firms will make it across the finish line.
